Last reviewed · How we verify
Oral N-Acetyl Cystein
N-Acetyl Cysteine acts as an antioxidant and mucolytic agent by replenishing intracellular glutathione levels and breaking disulfide bonds in mucus.
N-Acetyl Cysteine acts as an antioxidant and mucolytic agent by replenishing intracellular glutathione levels and breaking disulfide bonds in mucus. Used for Chronic obstructive pulmonary disease (COPD), Acetaminophen overdose.
At a glance
| Generic name | Oral N-Acetyl Cystein |
|---|---|
| Also known as | Trebon |
| Sponsor | Imam Khomeini Hospital |
| Drug class | antioxidant and mucolytic |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
N-Acetyl Cysteine provides cysteine, a precursor to glutathione, which is a critical intracellular antioxidant. It also functions as a mucolytic by disrupting disulfide bonds in mucus, making it less viscous and easier to clear from the airways.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Acetaminophen overdose
Common side effects
- Nausea
- Vomiting
Key clinical trials
- Efficacy Study of a Food Supplement With Myo-inositol, N-Acetyl-Cystein, Zinc and Vitamins on Sperm DNA Fragmentation (NA)
- N-Acetyl Cystein and Contrast Nephropathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral N-Acetyl Cystein CI brief — competitive landscape report
- Oral N-Acetyl Cystein updates RSS · CI watch RSS
- Imam Khomeini Hospital portfolio CI